Cellectis (NASDAQ:CLLS) Shares Cross Above Fifty Day Moving Average of $2.42

Cellectis S.A. (NASDAQ:CLLSGet Rating) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.42 and traded as high as $2.51. Cellectis shares last traded at $2.50, with a volume of 155,024 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Cellectis from $34.00 to $36.00 in a report on Thursday, August 18th. StockNews.com downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $15.17.

Cellectis Stock Up 15.2 %

The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $113.93 million, a price-to-earnings ratio of -1.09 and a beta of 2.01. The stock’s fifty day moving average price is $2.42 and its 200-day moving average price is $2.89.

Institutional Trading of Cellectis

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Jane Street Group LLC raised its position in Cellectis by 166.5% during the first quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock worth $2,789,000 after acquiring an additional 376,862 shares in the last quarter. State Street Corp raised its position in Cellectis by 112.2% during the second quarter. State Street Corp now owns 253,725 shares of the biotechnology company’s stock worth $718,000 after acquiring an additional 134,164 shares in the last quarter. Principal Financial Group Inc. raised its position in Cellectis by 11.0% during the second quarter. Principal Financial Group Inc. now owns 1,348,312 shares of the biotechnology company’s stock worth $3,816,000 after acquiring an additional 133,587 shares in the last quarter. Vanguard Group Inc. bought a new stake in Cellectis during the third quarter worth $197,000. Finally, Oppenheimer & Co. Inc. bought a new stake in Cellectis during the first quarter worth $339,000. 23.83% of the stock is owned by institutional investors.

About Cellectis

(Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Read More

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.